Foundational characteristics of cancer include proliferation, angiogenesis, migration, evasion of apoptosis, and cellular immortality. Find key markers for these cellular processes and antibodies to detect them.
The SUMOplot™ Analysis Program predicts and scores sumoylation sites in your protein. SUMOylation is a post-translational modification involved in various cellular processes, such as nuclear-cytosolic transport, transcriptional regulation, apoptosis, protein stability, response to stress, and progression through the cell cycle.
The Autophagy Receptor Motif Plotter predicts and scores autophagy receptor binding sites in your protein. Identifying proteins connected to this pathway is critical to understanding the role of autophagy in physiological as well as pathological processes such as development, differentiation, neurodegenerative diseases, stress, infection, and cancer.
KCNJ12 Antibody (C-term)
Affinity Purified Rabbit Polyclonal Antibody (Pab)
- SPECIFICATION
- CITATIONS
- PROTOCOLS
- BACKGROUND
Application 
| WB, E |
|---|---|
| Primary Accession | Q14500 |
| Other Accession | NP_066292.2 |
| Reactivity | Human |
| Host | Rabbit |
| Clonality | Polyclonal |
| Isotype | Rabbit IgG |
| Calculated MW | 49001 Da |
| Antigen Region | 405-433 aa |
| Gene ID | 3768 |
|---|---|
| Other Names | ATP-sensitive inward rectifier potassium channel 12, Inward rectifier K(+) channel Kir22, IRK-2, Inward rectifier K(+) channel Kir22v, Potassium channel, inwardly rectifying subfamily J member 12, KCNJ12, IRK2, KCNJN1 |
| Target/Specificity | This KCNJ12 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 405-433 amino acids from the C-terminal region of human KCNJ12. |
| Dilution | WB~~1:1000 |
| Format | Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification. |
| Storage | Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles. |
| Precautions | KCNJ12 Antibody (C-term) is for research use only and not for use in diagnostic or therapeutic procedures. |
| Name | KCNJ12 |
|---|---|
| Synonyms | IRK2, KCNJN1 |
| Function | Inward rectifying potassium channel that is activated by phosphatidylinositol 4,5-bisphosphate and that probably participates in controlling the resting membrane potential in electrically excitable cells. Probably participates in establishing action potential waveform and excitability of neuronal and muscle tissues. Inward rectifier potassium channels are characterized by a greater tendency to allow potassium to flow into the cell rather than out of it. Their voltage dependence is regulated by the concentration of extracellular potassium; as external potassium is raised, the voltage range of the channel opening shifts to more positive voltages. The inward rectification is mainly due to the blockage of outward current by internal magnesium. |
| Cellular Location | Membrane; Multi-pass membrane protein. Cell membrane; Multi-pass membrane protein |
Thousands of laboratories across the world have published research that depended on the performance of antibodies from Abcepta to advance their research. Check out links to articles that cite our products in major peer-reviewed journals, organized by research category.
info@abcepta.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
Background
This gene encodes an inwardly rectifying K+ channel which may be blocked by divalent cations. This protein is thought to be one of multiple inwardly rectifying channels which contribute to the cardiac inward rectifier current (IK1). The gene is located within the Smith-Magenis syndrome region on chromosome 17.
References
Collins, A., et al. J. Cell. Physiol. 219(1):8-13(2009)
Ji, W., et al. Nat. Genet. 40(5):592-599(2008)
Panama, B.K., et al. J. Physiol. (Lond.) 571 (PT 2), 287-302 (2006) :
Kiesecker, C., et al. J. Mol. Med. 84(1):46-56(2006)
Kubo, Y., et al. Pharmacol. Rev. 57(4):509-526(2005)
If you have used an Abcepta product and would like to share how it has performed, please click on the "Submit Review" button and provide the requested information. Our staff will examine and post your review and contact you if needed.
If you have any additional inquiries please email technical services at tech@abcepta.com.
Ordering Information
Other Products
Shipping Information
